Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Heather D. Turner
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Beta
- 0.42
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 19.51
Financials
LBRX has only 9 quarterly periods on file — the charts below show the full history available.
Net Income
$-51.60MEBITDA
$-53.82MFree Cash Flow
$-37.99MEPS (diluted)
$-1.71Shares Outstanding (diluted)
30.14M+751.2%Operating Expenses
$53.82MCash & Debt
$327.79MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-25.20M | $-1.00 |
| 2024 | $0.00 | $-63.10M | $-17.83 |
| 2023 | $0.00 | $-6.28M | $-1.77 |
| 2022 | $0.00 | $-14.35M | $-4.05 |
Valuation
LBRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·4d ago·Neutral
LB Pharmaceuticals to Participate in Upcoming Investor Events NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
…ng LB‑102 with a Focus on Schizophrenia Treatment NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. …
View source ↗ - Newsseekingalpha.com·31d ago·Positive
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain receptor occupancy at much lower doses than amisulpride, supporting once-daily dosing and potentially fewer side effects. The main investment debate centers on whether the R-enantiomer's 5-HT7
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
LB Pharmaceuticals to Participate in Upcoming September Investor Events NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-1.62 per share
Typical surprise -3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-1.71 vs $-0.80miss
- Tue, May 12$-0.67 vs $-0.75beat
- Thu, Mar 26$-0.45 vs $-0.45beat
- Thu, Nov 6$-0.61 vs $-0.57miss
Estimates and results for LBRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LBRX officers and directors.
- Bought
- $29
- Sold
- —
1 trade
0 trades
- Deep Track Biotechnology Master Fund, Ltd.bought
4 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LBRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.